Section Arrow
BLTE.NASDAQ
- Belite Bio
Quotes are at least 15-min delayed:2026/01/02 03:29 EST
Regular Hours
Last
 159.96
-0.86 (-0.53%)
Day High 
161.8 
Prev. Close
160.82 
1-M High
169.75 
Volume 
60.95K 
Bid
--
Ask
--
Day Low
158.21 
Open
159.8 
1-M Low
130.06 
Market Cap 
6.03B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 155.99 
20-SMA 152.2 
50-SMA 127.77 
52-W High 169.75 
52-W Low 49 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.92/0.79
Enterprise Value
6.03B
Balance Sheet
Book Value Per Share
7.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.